Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L G Rider

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Neurology|July 28, 2004
Polymyositis: an overdiagnosed entityF W Miller, L G Rider, P H Plotz, et al.
Rheumatology (Oxford, England)|November 16, 2001
Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathiesF W Miller, L G Rider, Y L Chung, et al.
Arthritis and Rheumatism|November 19, 1997
Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study GroupL G Rider, B M Feldman, M D Perez, et al.
Rheumatology (Oxford, England)|September 25, 2007
The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathyA M Huber, E M Dugan, P A Lachenbruch, et al.
Rheumatology (Oxford, England)|December 17, 2008
Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositisM O Harris-Love, J A Shrader, D Koziol, et al.
Arthritis and Rheumatism|October 19, 1999
Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study GroupD J Lovell, C B Lindsley, R M Rennebohm, et al.
Arthritis and Rheumatism|April 29, 1998
Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathyL G Rider, R C Gurley, J P Pandey, et al.
The Journal of Rheumatology|May 22, 2001
Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study GroupA M Huber, J E Hicks, P A Lachenbruch, et al.
The British Journal of Dermatology|April 20, 2017
Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologistsJ Tiao, R Feng, E M Berger, et al.
Genes and Immunity|August 21, 2015
Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypesF W Miller, W Chen, T P O'Hanlon, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Neurology|July 28, 2004
Polymyositis: an overdiagnosed entityF W Miller, L G Rider, P H Plotz, et al.
Rheumatology (Oxford, England)|November 16, 2001
Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathiesF W Miller, L G Rider, Y L Chung, et al.
Arthritis and Rheumatism|November 19, 1997
Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study GroupL G Rider, B M Feldman, M D Perez, et al.
Rheumatology (Oxford, England)|September 25, 2007
The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathyA M Huber, E M Dugan, P A Lachenbruch, et al.
Rheumatology (Oxford, England)|December 17, 2008
Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositisM O Harris-Love, J A Shrader, D Koziol, et al.
Arthritis and Rheumatism|October 19, 1999
Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study GroupD J Lovell, C B Lindsley, R M Rennebohm, et al.
Arthritis and Rheumatism|April 29, 1998
Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathyL G Rider, R C Gurley, J P Pandey, et al.
The Journal of Rheumatology|May 22, 2001
Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study GroupA M Huber, J E Hicks, P A Lachenbruch, et al.
The British Journal of Dermatology|April 20, 2017
Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologistsJ Tiao, R Feng, E M Berger, et al.
Genes and Immunity|August 21, 2015
Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypesF W Miller, W Chen, T P O'Hanlon, et al.
Pageof 4